SCHEMBL4720203

SCHEMBL4720203

CCCOc1ccccc1C1CNCC[N]1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2B P41595 3/20 0.45
HTR2C P28335 2/20 0.45
HTR2A P28223 2/20 0.40
LMNA P02545 4/20 0.39
SMN1; SMN2 Q16637 4/20 0.38
TSHR P16473 3/20 0.38
HTR1D P28221 2/20 0.38
HTR1B P28222 2/20 0.38
TP53 P04637 2/20 0.38
NPSR1 Q6W5P4 2/20 0.38
MAPK1 P28482 2/20 0.38
ALOX15 P16050 1/20 0.38
RAB9A P51151 1/20 0.38
SLC6A2 P23975 3/20 0.37
SLC6A4 P31645 3/20 0.37
SLC6A3 Q01959 3/20 0.37
KCNH2 Q12809 1/20 0.37
MRGPRX1 Q96LB2 1/20 0.37
ALDH1A1 P00352 2/20 0.36
CYP1A2 P05177 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4723022 0.93 TP53 (0.41) HTR2BHTR2CHTR2ALMNATSHR
SCHEMBL2204690 0.89 SLC6A2 (0.46) HTR2BHTR2CHTR2ALMNATSHR
SCHEMBL2200156 0.83 HTR1A (0.37) HTR2BHTR2CHTR2ALMNATSHR
SCHEMBL1254378 0.81 HTR2C (0.51) HTR2BHTR2CHTR2ASLC6A2SLC6A4
SCHEMBL446838 0.81 SLC6A4 (0.57) HTR2BHTR2CHTR2ALMNATSHR
SCHEMBL4721419 0.79 HTR2C (0.48) HTR2BHTR2CHTR2ALMNASMN1; SMN2
SCHEMBL4765412 0.78 HTR2C (0.47) HTR2BHTR2CLMNASMN1; SMN2TSHR
SCHEMBL4720767 0.78 HTR1D (0.48) HTR2BHTR2CHTR2ALMNASMN1; SMN2
SCHEMBL6361061 0.76 ADRA2B (0.39) HTR2BHTR2CHTR2ASLC6A2SLC6A4
SCHEMBL10518986 0.75 MAOA (0.56) LMNASMN1; SMN2RAB9AALDH1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors PFIZER INC. 2008-07-24 US disclosed
EP-1874780-A1 4-PIPERAZINYLTHIENO[2,3-D]PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS Pharmacia & Upjohn Company LLC (US) 2008-01-09 EP disclosed
WO-2006100591-A1 4-PIPERAZINNYLTHIENO [2,3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS PHARMACIA & UPJOHN COMPANY LLC (US) 2006-09-28 WO disclosed
EP-0273444-A2 Use of carboxamide compounds for the preparation of a medicament for treating hyperlipidemia OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) 1988-07-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors TBXA2R, P2RY4, PF4 HTR2B 242/4885HTR2C 215/4885HTR2A 151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.